Speaker Profile
CEO, Bluestar Genomics
Biography
Dave is a life sciences industry veteran with an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings. Most recently, he was president and chief executive officer of Omniome, where he guided and scaled the DNA sequencing company from the early technology development stage through the delivery of its beta prototype and ultimately leading to its sale to PacBio in 2021. Prior to Omniome, Dave served as the president and chief operating officer of Ariosa Diagnostics, a diagnostics company focused on the cell-free DNA non-invasive prenatal testing that was acquired by Roche in 2014. Post-acquisition, Dave served as lifecycle leader, site head, and a core member of the Roche Sequencing Solutions leadership team. He has also held positions at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceuticals Sciences.
Talk
Epigenomic Cancer Detection as Next Generation Liquid Biopsy
Dynamic DNA demethylation events can be measured in an unbiased accurate manner through click-chemistry based detection of 5-hydromethylcytosine (5hmC). Our novel epigenomics technology platform combines machine learning with our proprietary 5hmC biomarker analysis and other biomarker feature sets to provide a precise screening method that can detect cancer earlier than established methods.
Session Abstract – PMWC 2022 Silicon Valley
The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.
Sessions:
- Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
Session Chair: Jimmy Lin, Freenome
- Peter Bach, Delfi Diagnostics
- Ash Alizadeh, Stanford
- Amir Ali Talasaz, Guardant Health
- Anne-Renee Hartman, Adela
- How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
Session Chair: Rebecca Brandes, Agilent
- Edward Abrahams, PMC
- Blandine Merino, Agilent
- Adrian Lee, UPMC - The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
- Minetta Liu, Natera - Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
Session Chair: Sam Salman, miR Scientific
- Frederick Baehner, Exact Sciences
- The Advantages of Exosomes as a Liquid Biopsy Based Markers
Session Chair: Johan Skog, Exosome Diagnostics
- Jamil Azzi, Harvard
- Dolores Di Vizio, Cedars-Sinai Medical Center
- Showcase
- Dave Mullarkey, Bluestar Genomics
- Stephane Mouradian, Personalis
- Michael Dugan, Biocept
- Priti Hegde, Foundation Medicine
- Steven Soper, The University of Kansas
- Maggie Rougier-Chapman, Personal Genome Diagnostics
- Daniel Kim, UCSC
